Binkui Li

Specializzazione: Hepatobiliary surgeon
Studio medico: Cina, Canton, Sun Yat-sen University Cancer Center (SYSUCC)
In qualità di professore, supervisore di dottorato e direttore del Dipartimento di Chirurgia Epatica presso il Sun Yat-sen University Cancer Center, Binkui Li guida l'assistenza multidisciplinare per il cancro al fegato, combinando la chirurgia con la terapia interventistica vascolare, la terapia mirata e l'immunoterapia. Il suo focus clinico include la terapia di conversione per il cancro al fegato avanzato, volta a creare opportunità chirurgiche per casi inizialmente non resecabili, ed è un membro esperto del team multidisciplinare (MDT) per il cancro colorettale, inclusa la chirurgia delle metastasi epatiche da cancro colorettale.
Binkui Li è uno specialista presso il Sun Yat-sen University Cancer Center, dove ricopre il ruolo di professore, supervisore di dottorato e direttore di Chirurgia Epatica. Tratta i tumori al fegato con un programma multidisciplinare che combina chirurgia, terapia interventistica vascolare, terapia mirata e immunoterapia. Un elemento distintivo è il suo approccio di terapia di conversione per il cancro al fegato avanzato, che rende possibile l'intervento chirurgico in casi inizialmente inoperabili.

Servizi medici

Com'è andata la tua esperienza?

1 di 3

Le informazioni su questo medico sono complete e chiare

Totalmente in disaccordo

Totalmente d'accordo

Formazione accademica

With conversion therapy designed to turn initially unresectable advanced liver cancers into operable cases, Binkui Li focuses on the “multidisciplinary, individualized, systemic treatment” pathway for every patient at Sun Yat-sen University Cancer Center. As Professor, PhD supervisor, and Director of the Liver Surgery Department, he coordinates liver cancer treatment that can include surgery, vascular interventional therapy, targeted therapy, and immunotherapy. His work emphasizes improving curative outcomes and quality of life by tailoring treatment programs to disease stage and biology. Among his core clinical priorities is conversion therapy for advanced liver cancer, which is intended to create surgery opportunities for cases that cannot be resected at presentation. He also participates as an expert member of the Multi-Disciplinary Team (MDT) for colorectal cancer, where he is skilled in surgery of liver metastasis from colorectal cancer. In practice, this means patients are evaluated through a liver-focused surgical lens while systemic options are considered early as part of a single plan.

Education

Education details are not specified in the provided profile materials.

Work experience

Professor and Director of Liver Surgery Department, Sun Yat-sen University Cancer Center (current role).

Clinical focus and techniques

At Sun Yat-sen University Cancer Center, Binkui Li specializes in multidisciplinary management of liver cancers, integrating operative and non-operative oncologic strategies into one individualized plan.

Conversion therapy for advanced liver cancer to create surgery opportunities for initially unresectable cases.
Surgery of liver metastasis from colorectal cancer as part of colorectal cancer MDT decision-making.
Multidisciplinary treatment of liver cancers including surgery.
Vascular interventional therapy for liver cancer.
Targeted therapy and immunotherapy as components of systemic treatment programs.

Professional societies and certifications

Memberships and certifications are not specified in the provided profile materials.

Academic output

Academic output details are not specified in the provided profile materials.

Courses and advanced training

Courses and advanced training details are not specified in the provided profile materials.

Awards and recognition

Awards are not specified in the provided profile materials.

For international patients, the advantage of working with a specialist at Sun Yat-sen University Cancer Center is access to coordinated liver cancer decision-making across surgical and systemic options. The clinic’s liver surgery program is structured around multidisciplinary planning, which is especially relevant for advanced-stage disease where timing of conversion therapy and resection matters.